Generic Name
Tirzepatide
Brand Names
Mounjaro, Zepbound
FDA approval date: May 13, 2022
Classification: GLP-1 Receptor Agonist
Form: Injection
What is Mounjaro (Tirzepatide)?
MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
Summary: The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off ...
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD), a Phase 1b Study
Background: Glucagon-like peptide 1 (GLP-1) agonist drugs are used to treat diabetes and aid weight loss. They may also help reduce cravings for drugs and alcohol. Researchers want to know if a GLP-1 drug (tirzepatide) can lessen the urge to drink in people with alcohol use disorder (AUD).
Prediction of Response to GLP-1/GIP Receptor Agonists in Obesity Using Genetic Risk Score and SNP Profiling: A Prospective Cohort Study.
Summary: Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, are highly effective treatments for obesity, substantial inter-individual variability in weight loss response remains. Genetic factors may...
Related Latest Advances
Brand Information
Mounjaro (tirzepatide)
WARNING: RISK OF THYROID C-CELL TUMORS
- In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined[see Warnings and Precautions (
- MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[see Contraindications (. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO[see Contraindications (
1INDICATIONS AND USAGE
MOUNJARO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
2DOSAGE FORMS AND STRENGTHS
Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses:
3CONTRAINDICATIONS
MOUNJARO is contraindicated in patients with:
- A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO
4ADVERSE REACTIONS
The following serious adverse reactions are described below or elsewhere in the prescribing information:
- Risk of Thyroid C-cell Tumors
- Acute Pancreatitis
- Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
- Hypersensitivity Reactions
- Acute Kidney Injury Due to Volume Depletion
- Severe Gastrointestinal Adverse Reactions
- Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
- Acute Gallbladder Disease
- Pulmonary Aspiration During General Anesthesia or Deep Sedation
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
4.2Postmarketing Experience
The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypersensitivity: anaphylaxis, angioedema
Gastrointestinal: acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, severe constipation including fecal impaction
Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation
Renal: acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis
Skin and Subcutaneous Tissue: alopecia
5OVERDOSAGE
In the event of an overdosage, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Initiate appropriate supportive treatment according to the patient's clinical signs and symptoms. A period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days.
6DESCRIPTION
MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C
Structural formula:
MOUNJARO is a clear, colorless to slightly yellow, sterile solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO has a pH of 6.5 to 7.5.
Each single-patient-use KwikPen contains additional volume to allow for device priming.
7PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (
8Mounjaro Medication Guide
MOU-0009-MG-20260422
9Mounjaro Single-Dose Pen Instructions for Use
Important information you need to know before injecting MOUNJARO
Read this Instructions for Use and the Medication Guide before using your MOUNJARO Pen and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Talk to your healthcare provider about how to inject MOUNJARO the right way.
- MOUNJARO is a single-dose prefilled pen.
- MOUNJARO is used 1 time each week.
- Inject under the skin (subcutaneously) only.
- You or another person can inject into your stomach (abdomen) or thigh.
- Another person can inject into the back of your upper arm.
Guide to parts
Preparing to inject MOUNJARO
Storage and handling
- Store your Pen in the refrigerator between 36°F to 46°F (2°C to 8°C).
- You may store your Pen at room temperature up to 86°F (30°C) for up to a total of 21 days.
- Discard the Pen after a total of 21 days at room temperature.
- Do not freeze your Pen. If the Pen has been frozen, throw the Pen away and use a new Pen.
- Store your Pen in the original carton to protect your Pen from light.
- The Pen has glass parts. Handle it carefully. If you drop the Pen on a hard surface,
- Keep your MOUNJARO Pen and all medicines out of the reach of children.
Commonly asked questions
What if I see air bubbles in my Pen?
Air bubbles are normal.
What if my Pen is not at room temperature?
It is not necessary to warm the Pen to room temperature.
What if I unlock the Pen and press the purple injection button before pulling off the gray base cap?
Do not remove the gray base cap. Throw away the Pen and get a new Pen.
What if there is a drop of liquid on the tip of the needle when I remove the gray base cap?
A drop of liquid on the tip of the needle is normal.
Do I need to hold the injection button down until the injection is complete?
This is not necessary, but it may help you keep the Pen steady against your skin.
I heard more than 2 clicks during my injection—2 loud clicks and 1 soft one. Did I get my complete injection?
Some people may hear a soft click right before the second loud click. That is the normal operation of the Pen.
I am not sure if my Pen worked the right way.
What if there is a drop of liquid or blood on my skin after my injection?
This is normal. Press a cotton ball or gauze over the injection site.
Other information
• If you have vision problems,
Where to learn more
• If you have questions or problems with your MOUNJARO Pen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider.
• For more information about the MOUNJARO Pen, visit our website at www.mounjaro.com.
Marketed by:
Lilly USA, LLC
Indianapolis, IN 46285, USA
MOUNJARO is a registered trademark of Eli Lilly and Company.
Copyright © 2022, 2026, Eli Lilly and Company. All rights reserved.
This Instructions for Use has been approved by the U.S. Food and Drug Administration. Revised: April 2026
MOU-0004-IFU-20260422
10Mounjaro Single-Dose Vial Instructions for Use
Important information you need to know before injecting MOUNJARO
Read this Instructions for Use before you start taking MOUNJARO and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.
Talk to your healthcare provider about how to inject MOUNJARO the right way.
- MOUNJARO is a single-dose vial.
- MOUNJARO is used 1 time each week.
- Inject under the skin (subcutaneously) only.
- You or another person may inject into your stomach (abdomen) or thigh.
- Another person can inject into the back of your upper arm.
Gather supplies needed to give your injection
- 1 single-dose MOUNJARO vial
- 1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)
- 1 alcohol swab
- gauze
- 1 sharps container for throwing away used needles and syringes.
Note: The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.
Preparing to inject MOUNJARO
Remove the vial from the refrigerator.
Check the vial label to make sure you have the right medicine and dose, and that it has not expired.
Make sure the medicine:
Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.
Wash your hands with soap and water.
Injecting MOUNJARO
- Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.
- Change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
- Do not inject where the skin has pits, is thickened, or has lumps.
- Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
- Do not mix MOUNJARO with any other medicine.
- Do not inject MOUNJARO in the same injection site used for other medicines.
Disposing of used needles and syringes
- Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at:
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Storing MOUNJARO
- Store all unopened vials in the refrigerator at 36°F to 46°F (2°C to 8°C).
- You may store the unopened vial at room temperature up to 86°F (30°C) for up to a total of 21 days.
- Discard the vial after a total of 21 days at room temperature.
- Do not freeze. Do not use if MOUNJARO has been frozen.
- Store the vial in the original carton to protect from light.
- Throw away all opened vials after use, even if there is medicine left in the vial.
Keep MOUNJARO vials, syringes, needles, and all medicines out of the reach of children.
If you have any questions or problems with your MOUNJARO, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.
Marketed by:
MOUNJARO is a registered trademark of Eli Lilly and Company.
Copyright © 2023, 2026, Eli Lilly and Company. All rights reserved.
MON-VL-0003-IFU-20260422
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: April 2026
11Mounjaro Multiple-Dose Vial Instructions for Use
INSTRUCTIONS FOR USE
MOUNJARO®[mown-JAHR-OH]
(tirzepatide)
injection, for subcutaneous use
Multi-dose vial
Each vial contains 4 doses, one dose taken weekly.
Important information you need to know before injecting MOUNJARO
Read this Instructions for Use before you start taking MOUNJARO and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your needles or syringes with other people.
Talk to your healthcare provider about how to inject MOUNJARO the right way.
- MOUNJARO is a multi-dose vial.
- Inject
- You or another person may inject into your stomach (abdomen) or thigh.
- Another person can inject into the back of your upper arm.
Gather supplies needed to give your injection
- 1 multi-dose MOUNJARO vial
- 1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)
- 1 alcohol swab
- gauze
- 1 sharps container for throwing away used needles and syringes.
Note: The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.
Preparing to inject MOUNJARO
Check the vial label to make sure you have the right medicine and dose, and that it has not expired.
Make sure the medicine:
- is not frozen
- is colorless to slightly yellow
- is not cloudy
- does not have particles
Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.
Wash your hands with soap and water.
Injecting MOUNJARO
- Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.
- Change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.
- Do not inject where the skin has pits, is thickened, or has lumps.
- Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.
- Do not mix MOUNJARO with any other medicine.
- Do not inject MOUNJARO in the same injection site used for other medicines.
Disposing of used needles and syringes
- Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at:
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
Storing MOUNJARO
- Do not freeze. Do not use if MOUNJARO has been frozen.
- Store MOUNJARO in the original carton. Keep away from light.
Unopened vial:
- Store unopened vial in the refrigerator at 36°F to 46°F (2°C to 8°C). It can be used until the expiration date on the label if kept in the refrigerator.
- If stored at room temperature [up to 86°F (30°C)], throw away unopened vial after 30 days.
After vial has been opened:
- Store opened (in-use) vial in the original carton in the refrigerator at 36°F to 46°F (2°C to 8°C) or at room temperature [up to 86°F (30°C)]. Throw away opened vial after a total of 30 days at room temperature, 30 days after first use, or after taking 4 weekly doses, even if there is medicine left in it.
Keep MOUNJARO vials, syringes, needles, and all medicines out of the reach of children.
If you have any questions or problems with your MOUNJARO, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.
Marketed by:
MOUNJARO is a registered trademark of Eli Lilly and Company.
Copyright © 2026, Eli Lilly and Company. All rights reserved.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: January 2026
12Mounjaro KwikPen Multi-Dose Pen Instructions for Use
INSTRUCTIONS FOR USE
MOUNJARO
(tirzepatide)
injection, for subcutaneous use
multi-dose single-patient-use prefilled pen
Each pen contains 4 fixed doses, one dose taken weekly.
This Instructions for Use contains information on how to inject MOUNJARO.
Read this
- MOUNJARO KwikPen is a disposable multi-dose single-patient-use prefilled pen.
For your weekly dose, you need to turn the dose knob all the way until it stops AND the - After 4 doses, throw away (discard) the Pen, including the unused medicine. The Pen will prevent you from dialing a full dose after you have given yourself 4 weekly doses.
- Do not share your MOUNJARO Pen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.
- People who are blind or have vision problems should not use the Pen without help from a person trained to use the Pen.
Parts of the MOUNJARO Pen
Unused Pens:
- Store
- Unused Pens may be used until the expiration date (EXP) printed on the label if the Pen has been kept in the refrigerator.
- Do not freeze your Pen. Throw away (discard) the Pen if it has been frozen.
Used Pens:
- You may store your
- Keep away from heat and light.
- Keep your Pen and needles out of the sight and reach of children.
- Throw away the Pen 30 days after first use even though the Pen has medicine left in it.
- Throw away the Pen after receiving 4 weekly doses. Attempting to inject any leftover medicine could result in an incomplete dose even though the Pen still has medicine left in it.
- Put your used pen needles in an FDA-cleared sharps disposal container right away after use.
- Do not throw away (discard) loose pen needles in your household trash.
- Discard the used Pen in your household trash or FDA-cleared sharps disposal container after you have removed the needle.
- If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away (discard) used needles. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
- If you cannot remove the Pen cap, gently twist the Pen cap back and forth, and then pull the Pen cap straight off.
- If the dose knob is hard to push:
If the Pen prevents you from turning the dose knob until the - Throw away (discard) the Pen, including the unused medicine. There may not be enough medicine left in the pen to give a full dose.
Additional Information:
If you have any questions or problems with MOUNJARO KwikPen:
MOUNJARO
Marketed by:
Copyright ©2026, Eli Lilly and Company. All rights reserved.
MOUNJARO KwikPen meets the current dose accuracy and functional requirements of ISO 11608-1.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Revised: January 2026
MOUKP-0002-IFU-20260121
13PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 2.5 mg/0.5 mL Dose
NDC 0002-1506-80
Mounjaro
(tirzepatide) injection
2.5 mg/0.5 mL
Use one pen every week.
4 Single-dose prefilled pens
4 x 2.5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Lilly
14PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 5 mg/0.5 mL Dose
NDC 0002-1495-80
Mounjaro
(tirzepatide) injection
5 mg/0.5 mL
Use one pen every week.
4 Single-dose prefilled pens
4 x 5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Lilly
15PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 7.5 mg/0.5 mL Dose
NDC 0002-1484-80
Mounjaro
(tirzepatide) injection
7.5 mg/0.5 mL
Use one pen every week.
4 Single-dose prefilled pens
4 x 7.5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Lilly
16PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 10 mg/0.5 mL Dose
NDC 0002-1471-80
Mounjaro
(tirzepatide) injection
10 mg/0.5 mL
Use one pen every week.
4 Single-dose prefilled pens
4 x 10 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Lilly
17PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 12.5 mg/0.5 mL Dose
NDC 0002-1460-80
Mounjaro
(tirzepatide) injection
12.5 mg/0.5 mL
Use one pen every week.
4 Single-dose prefilled pens
4 x 12.5 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Lilly
18PACKAGE LABEL - Mounjaro Prefilled Pen (Autoinjector) - 15 mg/0.5 mL Dose
NDC 0002-1457-80
Mounjaro
(tirzepatide) injection
15 mg/0.5 mL
Use one pen every week.
4 Single-dose prefilled pens
4 x 15 mg/0.5 mL prefilled pens
Rx Only
For Subcutaneous Use
Dispense enclosed Medication Guide to each patient.
Lilly
19PACKAGE LABEL - Mounjaro Single-Dose Vial - 2.5 mg/0.5 mL Dose
NDC 0002-1152-01
Mounjaro
(tirzepatide) injection
2.5 mg/0.5 mL
Single-dose Vial - discard unused portion
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
20PACKAGE LABEL - Mounjaro Single-Dose Vial - 5 mg/0.5 mL Dose
NDC 0002-1243-01
Mounjaro
(tirzepatide) injection
5 mg/0.5 mL
Single-dose Vial - discard unused portion
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
21PACKAGE LABEL - Mounjaro Single-Dose Vial - 7.5 mg/0.5 mL Dose
NDC 0002-2214-01
Mounjaro
(tirzepatide) injection
7.5 mg/0.5 mL
Single-dose Vial - discard unused portion
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
22PACKAGE LABEL - Mounjaro Single-Dose Vial - 10 mg/0.5 mL Dose
NDC 0002-2340-01
Mounjaro
(tirzepatide) injection
10 mg/0.5 mL
Single-dose Vial - discard unused portion
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
23PACKAGE LABEL - Mounjaro Single-Dose Vial - 12.5 mg/0.5 mL Dose
NDC 0002-2423-01
Mounjaro
(tirzepatide) injection
12.5 mg/0.5 mL
Single-dose Vial - discard unused portion
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
24PACKAGE LABEL - Mounjaro Single-Dose Vial - 15 mg/0.5 mL Dose
NDC 0002-3002-01
Mounjaro
(tirzepatide) injection
15 mg/0.5 mL
Single-dose Vial - discard unused portion
Rx Only
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
25PACKAGE LABEL - Mounjaro Multi-Dose Vial - 2.5 mg/0.6 mL Dose (10 mg/2.4 mL [4.17 mg/mL])
Rx Only
NDC 0002-4052-11
Mounjaro
(tirzepatide) injection
10 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Mounjaro Multi-Dose Vial - 2.5 mg/0.6 mL Dose (10 mg/2.4 mL [4.17 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=moun-cart-mdv-2.5mg-nl085.jpg&setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
26PACKAGE LABEL - Mounjaro Multi-Dose Vial - 5 mg/0.6 mL Dose (20 mg/2.4 mL [8.33 mg/mL])
Rx Only
NDC 0002-4103-11
Mounjaro
(tirzepatide) injection
20 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Mounjaro Multi-Dose Vial - 5 mg/0.6 mL Dose (20 mg/2.4 mL [8.33 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=moun-cart-mdv-5mg-nl086.jpg&setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
27PACKAGE LABEL - Mounjaro Multi-Dose Vial - 7.5 mg/0.6 mL Dose (30 mg/2.4 mL [12.5 mg/mL])
Rx Only
NDC 0002-4210-11
Mounjaro
(tirzepatide) injection
30 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Mounjaro Multi-Dose Vial - 7.5 mg/0.6 mL Dose (30 mg/2.4 mL [12.5 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=moun-cart-mdv-7.5mg-nl087.jpg&setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
28PACKAGE LABEL - Mounjaro Multi-Dose Vial - 10 mg/0.6 mL Dose (40 mg/2.4 mL [16.7 mg/mL])
Rx Only
NDC 0002-4304-11
Mounjaro
(tirzepatide) injection
40 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Mounjaro Multi-Dose Vial - 10 mg/0.6 mL Dose (40 mg/2.4 mL [16.7 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=moun-cart-mdv-10mg-nl088.jpg&setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
29PACKAGE LABEL - Mounjaro Multi-Dose Vial - 12.5 mg/0.6 mL Dose (50 mg/2.4 mL [20.8 mg/mL])
Rx Only
NDC 0002-4523-11
Mounjaro
(tirzepatide) injection
50 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Mounjaro Multi-Dose Vial - 12.5 mg/0.6 mL Dose (50 mg/2.4 mL [20.8 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=moun-cart-mdv-12.5mg-nl089.jpg&setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)
30PACKAGE LABEL - Mounjaro Multi-Dose Vial - 15 mg/0.6 mL Dose (60 mg/2.4 mL[25 mg/mL])
Rx Only
NDC 0002-4612-11
Mounjaro
(tirzepatide) injection
60 mg/2.4 mL
ATTENTION:
For Subcutaneous Use
Needles and Syringes are not included
Dispense enclosed Medication Guide to each patient.
Lilly
![PACKAGE LABEL - Mounjaro Multi-Dose Vial - 15 mg/0.6 mL Dose (60 mg/2.4 mL [25 mg/mL])](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=moun-cart-mdv-15mg-nl090.jpg&setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0)